ArsenalBio plans to advance their lead programs through development invests in candidates for solid tumor cancers based on its proprietary T cell engineering technology; eGenesis moves to a first-in-human study for kidney transplant; SpectraWAVE will advance commercial expansion and product additions to their 510k-cleared HyperVue Imaging System; and more. $390M: Series A for T-Cell Engager […]
